CL2023001745A1 - Composición farmacéutica de agonistas duales de glp-1/glp-2 - Google Patents

Composición farmacéutica de agonistas duales de glp-1/glp-2

Info

Publication number
CL2023001745A1
CL2023001745A1 CL2023001745A CL2023001745A CL2023001745A1 CL 2023001745 A1 CL2023001745 A1 CL 2023001745A1 CL 2023001745 A CL2023001745 A CL 2023001745A CL 2023001745 A CL2023001745 A CL 2023001745A CL 2023001745 A1 CL2023001745 A1 CL 2023001745A1
Authority
CL
Chile
Prior art keywords
glp
agonists
pharmaceutical composition
dual
dual glp
Prior art date
Application number
CL2023001745A
Other languages
English (en)
Inventor
Skodborg Villadsen Jesper
Giehm Lise
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of CL2023001745A1 publication Critical patent/CL2023001745A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden conservantes particulares.
CL2023001745A 2020-12-16 2023-06-14 Composición farmacéutica de agonistas duales de glp-1/glp-2 CL2023001745A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20214558 2020-12-16

Publications (1)

Publication Number Publication Date
CL2023001745A1 true CL2023001745A1 (es) 2024-01-19

Family

ID=74141273

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001745A CL2023001745A1 (es) 2020-12-16 2023-06-14 Composición farmacéutica de agonistas duales de glp-1/glp-2

Country Status (12)

Country Link
US (1) US20230405088A1 (es)
EP (1) EP4262746A1 (es)
JP (1) JP2023553563A (es)
KR (1) KR20230121824A (es)
CN (1) CN116723850A (es)
AU (1) AU2021401137A1 (es)
CA (1) CA3196989A1 (es)
CL (1) CL2023001745A1 (es)
IL (1) IL301891A (es)
MX (1) MX2023006280A (es)
TW (1) TW202241491A (es)
WO (1) WO2022129312A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202315882A (zh) * 2021-09-03 2023-04-16 丹麥商西蘭製藥公司 給藥方案

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
KR20200080331A (ko) * 2012-07-23 2020-07-06 질랜드 파마 에이/에스 글루카곤 유사체
US10039809B2 (en) * 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
CN117384274A (zh) 2016-12-09 2024-01-12 西兰制药公司 酰化的glp-1/glp-2双重激动剂

Also Published As

Publication number Publication date
JP2023553563A (ja) 2023-12-22
MX2023006280A (es) 2023-06-13
CN116723850A (zh) 2023-09-08
TW202241491A (zh) 2022-11-01
US20230405088A1 (en) 2023-12-21
AU2021401137A1 (en) 2023-06-08
WO2022129312A1 (en) 2022-06-23
KR20230121824A (ko) 2023-08-21
EP4262746A1 (en) 2023-10-25
CA3196989A1 (en) 2022-06-23
IL301891A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
BR112019006194A2 (pt) composições que compreendem um ligante de ligação ao receptor de canabinóides
CL2023001746A1 (es) Composición farmacéutica de agonistas duales de glp 1/glp 2
CL2021001430A1 (es) Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422)
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
CR20150625A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
CL2023001745A1 (es) Composición farmacéutica de agonistas duales de glp-1/glp-2
CL2023001747A1 (es) Composición farmacéutica de agonistas duales de glp-1/glp-2
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
GT201300096A (es) Composiciones farmaceuticas que contienen un inhibidor de dgat1
BR112015023387A2 (pt) composições lipídicas de racecodotril
ECSP18034035A (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico
CL2021003273A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
BR112015022520A2 (pt) composições de ligante e métodos para produzir e usar as mesmas
ECSP099561A (es) Formulación de nevirapina de liberación prolongada
CL2019002514A1 (es) Composiciones cosméticas para el cuidado de la piel.
CL2021002946A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
DOP2010000088A (es) Compuesto inhibidor de fosforilasa de glicógeno y composición farmacéutica del mismo.
CL2019002516A1 (es) Composiciones cosméticas para el cuidado de la piel.
BR112023001471A2 (pt) Composição farmacêutica de anticorpo anti-pd-1 e uso da mesma
BR112022004777A2 (pt) Composição de micela de estimulação imunológica
CO2023000239A2 (es) Excipientes reductores de viscosidad y combinaciones de los mismos para formulaciones de proteína altamente concentradas
DOP2019000156A (es) Fenitoina topica para uso en el tratamiento del dolor neuropático periférico
BR112021022193A2 (pt) Composições tópicas